|
Video: What is a Stock Split?
|
|
Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and iovera°®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve. According to our PCRX split history records, Pacira BioSciences has had 0 splits. | |
|
Pacira BioSciences (PCRX) has 0 splits in our PCRX split history database.
Looking at the PCRX split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Pacira BioSciences shares, starting with a $10,000 purchase of PCRX, presented on a split-history-adjusted basis factoring in the complete PCRX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$67.01 |
|
End price/share: |
$25.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-61.95% |
|
Average Annual Total Return: |
-9.21% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,806.23 |
|
Years: |
10.00 |
|
|
|
|
|